BioArctic AB's partner, Eisai, has announced the approval of Leqembi (generic name: lecanemab) for the treatment of Alzheimer's disease in Israel.
Leqembi treatment should begin in patients diagnosed with mild cognitive impairment (MCI) or those in the mild dementia stage of Alzheimer's, aligning with the population in which clinical trials were conducted. Israel joins the ranks of the United States, Japan, China, South Korea, and Hong Kong in approving Leqembi.
This approval is underpinned by the significant outcomes of the global Phase 3 Clarity AD study. In this study, Leqembi successfully achieved its primary endpoint as well as all key secondary endpoints, demonstrating statistically significant results.
